REFERENCES:

[1] Kang L, Gao Z, Huang W, Jin M, Wang Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B 2015; 5:169–75.
[2] Weng Y, Liu J, Jin S, Guo W, Liang X, Hu Z. Nanotechnology based strategies for treatment of ocular disease. Acta Pharm Sin B 2017; 7:281–91.
[3] Fang J, Qin H, Nakamura H, Tsukigawa K, Shin T, Maeda H. Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors. Cancer Sci 2012; 103:535–41.
[4] Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Bio Pharm Bull 2013; 36:715–8.
[5] Chen MC, Lin ZW, Ling MH. Near-infrared light-activatable microneedle system for treating superficial tumors by combination of chemotherapy and photothermal therapy. ACS Nano 2016; 10:93–101.
[6] Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today 2005; 10:1451–8.
[7] Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discovery 2003; 2:214–21.
[8] Luk BT, Fang RH, Hu CM, Copp JA, Thamphiwatana S, Dehaini D, et al. Safe and immunocompatible nanocarriers cloaked in RBC membranes for drug delivery to treat solid tumors. Theragnostic 2016; 6:1004–11.
[9] Rao L, Bu LL, Cai B, Xu JH, Li A, Zhang WF, et al. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv Mater 2016; 28:3460–6.
[10] Jin K, Luo Z, Zhang B, Pang Z. Biomimetic nanoparticles for inflammation targeting. Acta Pharm Sin B 2018; 8:23–33.
[11] Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B 2016; 6:287–96.
[12] Huang Y, Gao X, Chen J. Leukocyte-derived biomimetic nanoparticulate drug delivery systems for cancer therapy. Acta Pharm Sin B 2018; 8:4–13.
[13] Ihler GM, Glew RH, Schnure FW. Enzyme loading of erythrocytes. Proc Natl Acad Sci U S A 1973; 70:2663–6.
[14] Pierigè F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev 2008; 60:286–95.
[15] Hamidi M, Tajerzadeh H. Carrier erythrocytes: an overview. Drug Deliv 2003; 10:9–20.
[16] Patel PD, Dand N, Hirlekar RS, KadamVJ.Drugloadederythrocytes: as novel drug delivery system. Curr Pharm Des 2008; 14:63–70.
[17] Dehaini D, Wei X, Fang RH, Masson S, Angsantikul P, Luk BT, et al. Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater 2017; 29:1606209.
[18] Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discovery 2011; 10:521–35.
[19] Wang C, Sun X, Cheng L, Yin S, Yang G, Li Y, et al. Multifunctional theragnostic red blood cells for magnetic-field-enhanced in vivo combination therapy of cancer. Adv Mater 2014; 26:4794–802.
[20] Sun X, Wang C, Gao M, Hu A, Liu Z. Remotely controlled red blood cell carriers for cancer targeting and near-infrared light triggered drug release in combined photothermal-chemotherapy. Adv FunctMater 2016; 12:548.
[21] Doshi N, Zahr AS, Bhaskar S, Lahann J, Mitragotri S. Red blood cell-mimicking synthetic biomaterial particles. Proc Natl Acad Sci USA2009; 106:21495–9.
[22] Tsai RK, Rodriguez PL, Discher DE. Self-inhibition of phagocytosis: the affinity of ‘marker of self’ CD47 for SIRP alpha dictates potency of inhibition but only at low expression levels. Blood Cells Mol Dis 2010;45:67–74.
[23] Merkel TJ, Jones SW, Herlihy KP, Kersey FR, Shields AR, Napier M, et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc Natl Acad Sci U S A 2011; 108:586–91.
[24] Marsden NV, Ostling SG. Accumulation of dextran in human red cells after haemolysis. Nature 1959;184(Suppl 10)723–4.
[25] Jain S, Jain NK. Engineered erythrocytes as a drug delivery system. Indian J Pharm Sci 1997; 59:275–81.
[26] Hu CM, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv Health Mater 2012; 1:537–47.
[27] Lejeune A, Moorjani M, Gicquaud C, Lacroix J, Poyet P, Gaudreault R. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res 1994; 14:915–9.
[28] Brown E. Integrin-associated protein (CD47): an unusual activator of G protein signalling. J Clin Investing 2001; 107:1499–500
[29] Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 2014; 32:25–50.
[30] Kroll AV, Fang RH, Zhang L. Bio interfacing and applications of cell membrane-coated nanoparticles. Bioconjugation Chem 2017; 28:23–32.
[31] Schonermark S, Rauterberg EW, Shin ML, Loke S, Roelcke D, Hansch GM. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136:1772–6.
[32] Zalman LS, Wood LM, Muller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A 1986; 83:6975–9.
[33]Kim DD, Miwa T, Kimura Y, Schwendener RA, Van LCM, Song WC. Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg. Blood 2008; 112:1109–19.
[34] Fang RH, Hu CM, Zhang L. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin Biol Ther 2012; 12:385–9.
[35] Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S A 2011; 108:10980–5.
[36] Ihler GM, Tsang HC. Hypotonic hemolysis methods for entrapment of agents in resealed erythrocytes. Methods Enzymol 1987; 149:221–9.
[37] Sato Y, Yamakose H, Suzuki Y. Mechanism of hypotonic hemolysis of human erythrocytes. Biol Pharm Bull 1993; 16:506–12.
[38] Seth M, Ramachandran A, Leal LG. Dilution technique to determine the hydrodynamic volume fraction of a vesicle suspension. Langmuir 2010; 26:15169–76.
[39] Bird J, Best R, Lewis DA. The encapsulation of insulin in erythrocytes. J Pharm Pharmacol 1983; 35:246–7.
[40] Gutierrez MC, Zarzuelo CA, Sayalero MM, Lanao JM. Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood Cells Mol Dis 2004; 33:132–40.
[41] Tajerzadeh H, Hamidi M. Evaluation of hypotonic preswelling method for encapsulation of enalaprilat in intact human erythrocytes. Drug Dev Ind Pharm 2000; 26:1247–57.
[42] Hamidi M, Zarrin AH, Foroozesh M, Zarei N, Mohammadi-Samani S. Preparation and in vitro evaluation of carrier erythrocytes for RES targeted delivery of interferon-α2b. Int J Pharm 2007;341:125–33.
[43] Franco RS, Barker R, Novick S, Weiner M, Martelo OJ. Effect of inositol hexaphosphate on the transient behaviour of red cells following a DMSO-induced osmotic pulse. J Cell Physiol 1986; 129:221–9.
[44] Watts TJ, Handy RD. The haemolytic effect of verapamil on erythrocytes exposed to varying osmolarity. Toxicol Vitr 2007; 21:835–9.
[45] Lynch AL, Chen R, Slater NK. pH-responsive polymers for trehalose loading and desiccation protection of human red blood cells. Biomaterials 2011;32:4443–9.
[46] Ren X, Zheng R, Fang X, Wang X, Zhang X, Yang W, et al. Red blood cell membrane camouflaged magnetic nanoclusters for imaging-guided photothermal therapy. Biomaterials 2016;92:13–24.
[47] Zhai Y, Su J, Ran W, Zhang P, Yin Q, Zhang Z, et al. Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theragnostic 2017; 7:2575–92.
[48] Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle bio interfacing by platelet membrane cloaking. Nature 2015;526:118–21.
[49] Su J, Sun H, Meng Q, Yin Q, Tang S, Zhang P, et al. Long circulation red-blood-cell-mimetic nanoparticles with peptide-enhanced tumor penetration for simultaneously inhibiting growth and lung metastasis of breast cancer. Adv Funct Mater 2016; 26:1243–52.
[50] Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009; 19:507–14.
[51] Kelm S, Schauer R. Sialic acids in molecular and cellular interactions. Int Rev Cytol 1997; 175:137–240.
[52] Raveendran P, Fu J, Wallen SL. Completely “green” synthesis and stabilization of 2003;125:13940–1.
[53] Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm 2004;58:327–41.
[54] Luk BT, Hu CM, Fang RH, Dehaini D, Carpenter C, Gao W, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 2014; 6:2730–7.
[55] Hu CM, Fang RH, Luk BT, Chen KN, Carpenter C, Gao W, et al. ‘Marker-of-self’ functionalization of nanoscale particles through a top down cellular membrane coating approach. Nanoscale 2013; 5:2664–8.
[56] Rao L, Cai B, Bu LL, Liao QQ, Guo SS, Zhao XZ, et al. Microfluidic electroporation-facilitated synthesis of erythrocyte membrane-coated magnetic nanoparticles for enhanced imaging guided cancer therapy. ACS Nano 2017; 11:3496–505.
[57] Miyazaki J, Aihara H. Gene transfer into muscle by electroporation in vivo. Methods Mol Med 2002; 69:49–62.
[58] Zhang J, Gao W, Fang RH, Dong A, Zhang L. Synthesis of nanogels via cell membrane-templated polymerization. Small 2015; 11:4309–13.
[59] Hochmuth RM, Evans CA, Wiles HC, McCown JT. Mechanical measurement of red cell membrane thickness. Science 1983; 220:101–2.
[60] Zhou H, Fan Z, Lemons PK, Cheng H. A facile approach to functionalize cell membrane-coated nanoparticles. Theragnostic 2016; 6:1012–22.
[61] Gagneux P, Varki A. Evolutionary considerations in relating oligosaccharide diversity to biological function. Glycobiology 1999; 9:747–55.
[62] Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal “Self” peptides that inhibit phagocytic clear ance and enhance delivery of nanoparticles. Science 2013;339:971–5.
[63] Richards MJ, Hsia CY, Singh RR, Haider H, Kumpf J, Kawate T, et al. Membrane protein mobility and orientation preserved in supported bilayers created directly from cell plasma membrane blebs. Langmuir 2016; 32:2963–74.
[64] Kimmett T, Smith N, Witham S, Petukh M, Sarkar S, Alexov E. Problem web server: protein and membrane placement and orientation package. Compute Math Methods Med 2014; 2014:838259.
[65] Wang X, Li H, Liu X, Tian Y, Guo H, Jiang T, et al. Enhanced photothermal therapy of biomimetic polypyrrole nanoparticles through improving blood flow perfusion. Biomaterials 2017; 143:130–41.
[66] Zha Z, Deng Z, Li Y, Li C, Wang J, Wang S, et al. Biocompatible polypyrrole nanoparticles as a novel organic photoacoustic contrast agent for deep tissue imaging. Nanoscale 2013; 5:4462–7.
[67] Jin Y, Li Y, Ma X, Zha Z, Shi L, Tian J, et al. Encapsulating tantalum oxide into polypyrrole nanoparticles for X-ray CT/photo acoustic bimodal imaging-guided photothermal ablation of cancer. Biomaterials 2014;35:5795–804.
[68] Li J, Arnal B, Wei CW, Shang J, Nguyen TM, O’Donnell M, et al. Magneto-optical nanoparticles for cyclic magnetomotive photoacoustic tic imaging. ACS Nano 2015; 9:1964–76.
[69] Martinive P, De Wever J, Bouzin C, Baudelet C, Sonveaux P, Gregoire V, et al. Reversal of temporal and spatial heterogeneities in tumor perfusion identifies the tumor vascular tone as a tunable variable to improve drug delivery. Mol Cancer Ther 2006; 5:1620–7.
[70] Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, et al. Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 2004; 64:3209–14.
[71] Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 2012; 64:5–24.
[72] Hamid ZAA, Tham CY, Ahmad Z. Preparation and optimization of surface-engineered poly (lactic acid) microspheres as a drug delivery device. J Mater Sci 2018; 53:4745–58.
[73] Tawakkal IS, Cran MJ, Miltz J, Bigger SW. A review of poly (lactic acid)-based materials for antimicrobial packaging. J Food Sci 2014; 79:1477–90.
[74] Aryal S, Hu CM, Zhang L. Polymer–cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 2010; 4:251–8.
[75] Gao W, Chan JM, Farokhzad OC. pH-Responsive nanoparticles for drug delivery. Mol Pharm 2010; 7:1913–20.
[76]McCall RL, Sirianni RW. PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS. J Vis Exp 2013:51015.
[77] Alshamsan A. Nanoprecipitation is more efficient than emulsion solvent evaporation method to encapsulate cucurbitacin I in PLGA nanoparticles. Saudi Pharm J 2014; 22:219–22.
[78] Lin HJ, Wang JH, Wang CY, Wu YC. The preparation and characteristic of poly(lactide-co-glycolide) microspheres as novel antigen delivery systems. Int J Nanotechnol 2013;10:870–90.
[79] Xing L, Shi Q, Zheng K, Shen M, Ma J, Li F, et al. Ultrasound mediated microbubble destruction (UMMD) facilitates the delivery of CA19-9 targeted and paclitaxel loaded mPEG-PLGA-PLL nano particles in pancreatic cancer. Theragnostic 2016; 6:1573–87.
[80] Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004; 14:198–206.
[81] Riess JG. Oxygen carriers (“blood substitutes”)—raison d’etre, chemistry, and some physiology. Chem Rev 2001; 101:2797–920.
[82] Castro CI, Briceno JC. Perfluorocarbon-based oxygen carriers: review of products and trials. Artif Organs 2010;34:622–34.
[83] Ren H, Liu J, Li Y, Wang H, Ge S, Yuan A, et al. Oxygen self-enriched nanoparticles functionalized with erythrocyte membranes for long circulation and enhanced phototherapy. Acta Biomater 2017; 59:269–82.
[84] Gao M, Liang C, Song X, Chen Q, Jin Q, Wang C, et al. Erythrocyte-membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv Mater 2017; 29:1701429.
[85] Zhang Z, Qian H, Yang M, Li R, Hu J, Li L, et al. Gambogic acid loaded biomimetic nanoparticles in colorectal cancer treatment. Int J Nanomed 2017;12:1593–605.
[86] Gao L, Wang H, Nan L, Peng T, Sun L, Zhou J, et al. Erythrocyte membrane-wrapped pH sensitive polymeric nanoparticles for non-small cell lung cancer therapy. Bioconjug Chem 2017; 28:2591–8.
[87] Guo Y, Wang D, Song Q, Wu T, Zhuang X, Bao Y, et al. Erythrocyte membrane-enveloped polymeric nanoparticles as nano vaccine for induction of antitumor immunity against melanoma. ACS Nano 2015; 9:6918–33.
[88] Hao R, Xing R, Xu Z, Hou Y, Gao S, Sun S. Synthesis, functionalization, and biomedical applications of multifunctional magnetic nanoparticles. Adv Mater 2010; 22:2729–42.
[89] Sharifi S, Seyed Nejad H, Laurent S, Atyabi F, Saei AA, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for in vivo molecular and cellular imaging. Contrast Media Mol Imaging 2015; 10:329–55.
[90] Yoshida T, Sasayama T, Enpuku K. (Invited) Biological applications of magnetic nanoparticles for magnetic immunoassay and magnetic particle imaging. ECS Trans 2016; 75:39–47.
[91] Rao L, Bu LL, Xu JH, Cai B, Yu GT, Yu X, et al. red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small 2015; 11:6225–36.
[92] Owens DR, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307:93–102.
[93] Chu M, Shao Y, Peng J, Dai X, Li H, Wu Q, et al. Near-infrared laser light mediated cancer therapy by photothermal effect of Fe3O4 magnetic nanoparticles. Biomaterials 2013; 34:4078–88.
[94] Chen H, Burnett J, Zhang F, Zhang J, Paholak H, Sun D. Highly crystallized iron oxide nanoparticles as effective and biodegradable mediators for photothermal cancer therapy. J Mater Chem B 2014;2:757–65.
[95] Shen S, Wang S, Zheng R, Zhu X, Jiang X, Fu D, et al. Magnetic nanoparticle clusters for photothermal therapy with near-infrared irradiation. Biomaterials 2015;39:67–74.
[96] Ding H, Lv Y, Ni D, Wang J, Tian Z, Wei W, et al. Erythrocyte membrane-coated NIR-triggered biomimetic nano vectors with pro grammed delivery for photodynamic therapy of cancer. Nanoscale 2015;7:9806–15.
[97] Zhou Y, Quan G, Wu Q, Zhang X, Niu B, Wu B, et al. Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharm Sin B 2018; 8:165–77.
[98] Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y. Enhanced blood suspensibility and laser-activated rumor-specific drug release of theragnostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Theranostics 2017;7:523–37.
[99] Vernier PT, Levine ZA, Wu YH, Joubert V, Ziegler MJ, Mir LM, et al. Electroporating fields target oxidatively damaged areas in the cell membrane. PloS One 2009;4:e7966.
[100] Cheng L, Yang K, Li Y, Chen J, Wang C, Shao M, et al. Facile preparation of multifunctional upconversion nanoprobes for multi modal imaging and dual-targeted photothermal therapy. Angew Chem Int Ed Engl 2011; 50:7385–90.
[101] Yang Y, Zhao Q, Feng W, Li F. Luminescent chemodosimeters for bioimaging. Chem Rev 2013;113:192–270
[102] Yang D, Dai Y, Liu J, Zhou Y, Chen Y, Li C, et al. Ultra-small BaGdF5-based upconversion nanoparticles as drug carriers and multimodal imaging probes. Biomaterials 2014;35:2011–23.
[103] Rieffel J, Chen F, Kim J, Chen G, Shao W, Shao S, et al. Hexamodal imaging with porphyrin-phospholipid-coated up conversion nanoparticles. Adv Mater 2015;27:1785–90.
[104] Chen Z, Liu Z, Li Z, Ju E, Gao N, Zhou L, et al. Upconversion nanoprobes for efficiently in vitro imaging reactive oxygen species and in vivo diagnosing rheumatoid arthritis. Biomaterials 2015; 39:15–22.
[105] Zhang F, Braun GB, Shi Y, Zhang Y, Sun X, Reich NO, et al. Fabrication of Ag@SiO2@Y2O3: Er nanostructures for bioimaging: tuning of the upconversion fluorescence with silver nanoparticles. J Am Chem Soc 2010; 132:2850–1.
[106] Li J, Huang J, Ao Y, Li S, Miao Y, Yu Z, et al. Synergizing upconversion nanophotosensitizers with hyperbaric oxygen to remo del the extracellular matrix for enhanced photodynamic cancer therapy. ACS Appl Mater Interfaces 2018; 10:22985–96.
[107] Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl 2010; 49:3280–94.
[108] Dreaden EC, Alkilany AM, Huang X, Murphy CJ, El-Sayed MA. The golden age: gold nanoparticles for biomedicine. Chem Soc Rev 2012; 41:2740–79.
[109] Moon GD, Choi SW, Cai X, Li W, Cho EC, Jeong U, et al. A new theranostic system based on gold nanocages and phase-change materials with unique features for photoacoustic imaging and controlled release. J Am Chem Soc 2011; 133:4762–5.
[110] Pan L, Liu J, He Q, Shi J. MSN-mediated sequential vascular-to-cell nuclear-targeted drug delivery for efficient tumor regression. Adv Mater 2014; 26:6742–8.
[111] Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58:1456–9.
[112] Toth M, Sohail A, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography. Methods Mol Biol 2012; 878:121–35.
[113] Li LL, Xu JH, Qi GB, Zhao X, Yu F, Wang H. Core-shell supramolecular gelatin nanoparticles for adaptive and “on-demand” antibiotic delivery. ACS Nano 2014; 8:4975–83.